Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma
KM Dhodapkar, AD Cohen, A Kaushal, AL Garfall… - Blood Cancer …, 2022 - AACR
Chimeric antigen-receptor (CAR) T cells lead to high response rates in myeloma, but most
patients experience recurrent disease. We combined several high-dimensional approaches
to study tumor/immune cells in the tumor microenvironment (TME) of myeloma patients pre–
and post–B-cell maturation antigen (BCMA)-specific CAR T therapy. Lower diversity of
pretherapy T-cell receptor (TCR) repertoire, presence of hyperexpanded clones with
exhaustion phenotype, and BAFF+ PD-L1+ myeloid cells in the marrow correlated with …
patients experience recurrent disease. We combined several high-dimensional approaches
to study tumor/immune cells in the tumor microenvironment (TME) of myeloma patients pre–
and post–B-cell maturation antigen (BCMA)-specific CAR T therapy. Lower diversity of
pretherapy T-cell receptor (TCR) repertoire, presence of hyperexpanded clones with
exhaustion phenotype, and BAFF+ PD-L1+ myeloid cells in the marrow correlated with …
以上显示的是最相近的搜索结果。 查看全部搜索结果